Trials / Terminated
TerminatedNCT01191372
First-in-Human and Proof-of-Mechanism Study of ARC19499 Administered to Hemophilia Patients
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 17 (actual)
- Sponsor
- Baxalta now part of Shire · Industry
- Sex
- Male
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to examine the safety, tolerability and the way the body handles various single and multiple doses of ARC19499 in patients with hemophilia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | placebo control | sterile saline for injection |
| DRUG | ARC19499 | Anti-tissue factor pathway inhibitor (TFPI) aptamer |
Timeline
- Start date
- 2010-09-15
- Primary completion
- 2011-12-28
- Completion
- 2011-12-28
- First posted
- 2010-08-30
- Last updated
- 2021-05-05
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT01191372. Inclusion in this directory is not an endorsement.